Abbott Laboratories logo

Abbott Laboratories

ABT

NYSEHealthcareMedical - Devices

Previous close

$116.64

+$2.50 · +2.19%

Aug 21, 4:02 PM ET

ABT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

83

Deep Value

Momentum

38

Weakening

Sentiment

72

Bullish

Risk resilience

69

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Robert Ford
Listed since
Mar 17, 1980
Employees
115,000

Market position

Day range

Current $116.64

52-week range

Current $116.64

Open
$114.02
Previous close
$114.14
Volume
9.83M
0.79× average
Average volume
12.45M
Average daily volume
Market cap
201.83B USD
Beta
0.58
Market reference 1
50-day average
$99.9394
+16.71% above average
200-day average
$107.08
+8.93% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
225.43B USD
P/E (TTM)
37.5×
P/B (TTM)
3.98×
P/S (TTM)
4.33×
EV / EBITDA
19.51×
Earnings yield
2.98%
Free cash flow yield
3.38%
Dividend yield
2.13%

Profitability & efficiency

Gross margin
56.80%
Operating margin
17.03%
Net margin
11.65%
Return on equity
12.51%
Return on assets
7.52%
Return on invested capital
8.43%

Financial health

Debt / equity
0.64×
Current ratio
1.58×
Altman Z-score
3.49
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends60%43%27%10%Gross margin, FY2021: 53.89%Gross margin, FY2022: 51.14%Gross margin, FY2023: 49.96%Gross margin, FY2024: 50.83%Gross margin, FY2025: 55.51%Operating margin, FY2021: 21.36%Operating margin, FY2022: 19.16%Operating margin, FY2023: 16.04%Operating margin, FY2024: 16.27%Operating margin, FY2025: 18.16%Net margin, FY2021: 16.42%Net margin, FY2022: 15.88%Net margin, FY2023: 14.27%Net margin, FY2024: 31.95%Net margin, FY2025: 14.72%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 53.89%. Gross margin FY2022 51.14%. Gross margin FY2023 49.96%. Gross margin FY2024 50.83%. Gross margin FY2025 55.51%. Operating margin FY2021 21.36%. Operating margin FY2022 19.16%. Operating margin FY2023 16.04%. Operating margin FY2024 16.27%. Operating margin FY2025 18.16%. Net margin FY2021 16.42%. Net margin FY2022 15.88%. Net margin FY2023 14.27%. Net margin FY2024 31.95%. Net margin FY2025 14.72%.

Income trends

Revenue

44.33B USD+5.67%

Operating income

8.05B USD+17.92%

Net income

6.52B USD-51.32%
Income trends across reported periods48.19B USD32.75B USD17.3B USD1.86B USDRevenue, FY2021: 43.08B USDRevenue, FY2022: 43.65B USDRevenue, FY2023: 40.11B USDRevenue, FY2024: 41.95B USDRevenue, FY2025: 44.33B USDOperating income, FY2021: 9.2B USDOperating income, FY2022: 8.36B USDOperating income, FY2023: 6.44B USDOperating income, FY2024: 6.83B USDOperating income, FY2025: 8.05B USDNet income, FY2021: 7.07B USDNet income, FY2022: 6.93B USDNet income, FY2023: 5.72B USDNet income, FY2024: 13.4B USDNet income, FY2025: 6.52B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 43.08B USD. Revenue FY2022 43.65B USD. Revenue FY2023 40.11B USD. Revenue FY2024 41.95B USD. Revenue FY2025 44.33B USD. Operating income FY2021 9.2B USD. Operating income FY2022 8.36B USD. Operating income FY2023 6.44B USD. Operating income FY2024 6.83B USD. Operating income FY2025 8.05B USD. Net income FY2021 7.07B USD. Net income FY2022 6.93B USD. Net income FY2023 5.72B USD. Net income FY2024 13.4B USD. Net income FY2025 6.52B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue44.33B USD41.95B USD40.11B USD43.65B USD43.08B USD
Cost of goods sold19.72B USD20.63B USD20.07B USD21.33B USD19.86B USD
Gross profit24.61B USD21.33B USD20.04B USD22.32B USD23.21B USD
Research and development2.96B USD2.82B USD2.72B USD2.85B USD2.74B USD
Selling, general, and administrative12.38B USD11.65B USD10.88B USD11.11B USD11.28B USD
Operating expenses16.59B USD14.47B USD13.6B USD13.96B USD14.01B USD
Interest income230M USD344M USD385M USD183M USD43M USD
Interest expense341M USD603M USD698M USD315M USD410M USD
Depreciation and amortization2.75B USD3.22B USD3.24B USD3.27B USD3.54B USD
Operating income8.05B USD6.83B USD6.44B USD8.36B USD9.2B USD
Net income6.52B USD13.4B USD5.72B USD6.93B USD7.07B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 0 misses, 5 met estimates
Average EPS surprise
+1.11%
11 comparable reports
Latest EPS result
1.31
Estimate 1.28 · Beat by 2.34%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.561.381.191.01Q1 '25MetQ2 '25BeatQ3 '25MetQ4 '25MetQ1 '26MetQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 22, 2025: actual 1.34, estimate 1.34, surprise 0.00%, Met estimate. Q2 2025, reported Apr 16, 2025: actual 1.09, estimate 1.07, surprise +1.87%, Beat. Q3 2025, reported Jul 17, 2025: actual 1.26, estimate 1.26, surprise 0.00%, Met estimate. Q4 2025, reported Oct 15, 2025: actual 1.3, estimate 1.3, surprise 0.00%, Met estimate. Q1 2026, reported Jan 22, 2026: actual 1.5, estimate 1.5, surprise 0.00%, Met estimate. Q2 2026, reported Apr 16, 2026: actual 1.15, estimate 1.14, surprise +0.88%, Beat. Q3 2026, reported Jul 16, 2026: actual 1.31, estimate 1.28, surprise +2.34%, Beat. Q4 2026, reported Oct 21, 2026: actual —, estimate 1.42, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates13.51B12.29B11.06B9.84BQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 22, 2025: actual 10.97B USD, estimate 11.03B USD, surprise -0.52%, Miss. Q2 2025, reported Apr 16, 2025: actual 10.36B USD, estimate 10.41B USD, surprise -0.46%, Miss. Q3 2025, reported Jul 17, 2025: actual 11.14B USD, estimate 11.09B USD, surprise +0.45%, Beat. Q4 2025, reported Oct 15, 2025: actual 11.37B USD, estimate 11.39B USD, surprise -0.18%, Miss. Q1 2026, reported Jan 22, 2026: actual 11.46B USD, estimate 11.8B USD, surprise -2.89%, Miss. Q2 2026, reported Apr 16, 2026: actual 11.16B USD, estimate 11B USD, surprise +1.49%, Beat. Q3 2026, reported Jul 16, 2026: actual 12.59B USD, estimate 12.52B USD, surprise +0.59%, Beat. Q4 2026, reported Oct 21, 2026: actual —, estimate 12.99B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$123.64

6.00% upside
Past 12 months12-month forecastHigh $145Average $123.64Low $92.00

Rating distribution

41 ratings
Strong buy00%
Buy3278%
Hold922%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
Wolfe ResearchupgradePeer PerformOutperform
JP MorganmaintainOverweight

ABT news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$2.36

2025 complete year+31.1% since 2021

2026 partial: $1.89

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 15, 2026

$0.63

Quarterly

Record Jul 15, 2026 · Payment Aug 17, 2026

Dividend

Ex-dividend Apr 15, 2026

$0.63

Quarterly

Record Apr 15, 2026 · Payment May 15, 2026

Dividend

Ex-dividend Jan 15, 2026

$0.63

Quarterly

Record Jan 15, 2026 · Payment Feb 13, 2026

Dividend

Ex-dividend Oct 15, 2025

$0.59

Quarterly

Record Oct 15, 2025 · Payment Nov 17, 2025

Dividend

Ex-dividend Jul 15, 2025

$0.59

Quarterly

Record Jul 15, 2025 · Payment Aug 15, 2025

Dividend

Ex-dividend Apr 15, 2025

$0.59

Quarterly

Record Apr 15, 2025 · Payment May 15, 2025

ABT peers

ETFs holding ABT

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ABT

research.disclaimer